BR100 Increased By (0.06%)
BR30 Increased By (0.54%)
KSE100 Increased By (0.32%)
KSE30 Increased By (0.39%)
AGHA 6.40 Increased By ▲ 0.08 (1.27%)
BECO 4.37 Increased By ▲ 0.10 (2.34%)
BML 62.65 Increased By ▲ 0.20 (0.32%)
BOP 31.41 Increased By ▲ 0.18 (0.58%)
CNERGY 11.67 Increased By ▲ 0.08 (0.69%)
CSIL 5.85 Increased By ▲ 0.13 (2.27%)
FCCL 60.80 Decreased By ▼ -0.74 (-1.2%)
FFL 14.75 Decreased By ▼ -0.27 (-1.8%)
FNEL 1.21 Decreased By ▼ -0.02 (-1.63%)
KEL 6.32 Increased By ▲ 0.06 (0.96%)
KOSM 5.95 Increased By ▲ 0.39 (7.01%)
LOTCHEM 24.70 Increased By ▲ 0.02 (0.08%)
MLCF 103.50 Decreased By ▼ -0.58 (-0.56%)
NBP 173.16 Decreased By ▼ -2.12 (-1.21%)
NCPL 52.10 Decreased By ▼ -0.67 (-1.27%)
NPL 54.02 Decreased By ▼ -0.10 (-0.18%)
OGDC 316.40 Increased By ▲ 3.01 (0.96%)
PACE 9.20 No Change ▼ 0.00 (0%)
PAEL 35.70 Decreased By ▼ -0.10 (-0.28%)
PIBTL 13.60 Increased By ▲ 0.13 (0.97%)
PPL 226.51 Increased By ▲ 4.70 (2.12%)
PRL 80.30 Increased By ▲ 1.22 (1.54%)
PTC 46.70 Decreased By ▼ -0.15 (-0.32%)
SSGC 23.80 Decreased By ▼ -0.07 (-0.29%)
TBL 9.23 Decreased By ▼ -0.08 (-0.86%)
TELE 7.45 Increased By ▲ 0.06 (0.81%)
TPL 24.55 Decreased By ▼ -0.56 (-2.23%)
TPLP 12.85 Increased By ▲ 0.34 (2.72%)
TREET 26.15 Decreased By ▼ -0.10 (-0.38%)
TRG 53.25 Decreased By ▼ -0.19 (-0.36%)
By

SYDNEY: Australia has secured access to a "promising" potential coronavirus vaccine, the prime minister announced Tuesday, saying the country would manufacture it and offer free doses to the entire population.

Prime Minister Scott Morrison said Australia had reached a deal with Swedish-British pharmaceutical company AstraZeneca to receive the Covid-19 vaccine it is developing with Oxford University.

"The Oxford vaccine is one of the most advanced and promising in the world, and under this deal we have secured early access for every Australian," he said.

"If this vaccine proves successful we will manufacture and supply vaccines straight away under our own steam and make it free for 25 million Australians."

The Oxford vaccine is one of five globally in Phase 3 efficacy trials, and researchers hope to have results by the end of the year.

Comments

Comments are closed for this article.